AARD News - Candlesense

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeu...

Investor events

11 days ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

SAN DIEGO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeu...

What technical indicators or trading volume patterns are emerging in response to this news release? Is there any indication of changes in the competitive landscape that could affect Aardvark's market opportunity? How might the reported cash position and burn rate affect the need for future equity raises or debt financing?

Earnings

25 days ago

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeu...

What are the potential regulatory pathways and milestones for ARD-201, and how could they impact future share performance? How might the anticipated peer‑review publication influence analyst coverage and investor sentiment? Could the announced data trigger any new licensing or partnership discussions that might affect the company’s valuation?

Clinical trials

26 days ago